These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23687957)

  • 21. The thyroid imaging reporting and data system on US, but not the BRAFV600E mutation in fine-needle aspirates, is associated with lateral lymph node metastasis in PTC.
    Park VY; Kim EK; Moon HJ; Yoon JH; Kwak JY
    Medicine (Baltimore); 2016 Jul; 95(29):e4292. PubMed ID: 27442672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma.
    Choi YW; Kim YH; Lee J; Soh EY; Park TJ; Kim JH
    Hum Pathol; 2015 Oct; 46(10):1557-65. PubMed ID: 26297257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elevated BANCR expression levels have different effects on papillary thyroid carcinoma progression depending on the presence of the BRAFV600E mutation.
    Stojanović S; Šelemetjev S; Đorić I; Rončević J; Janković Miljuš J; Živaljević V; Išić Denčić T
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1835-1842. PubMed ID: 32651027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
    Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
    APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The synergic effect of BRAF
    Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
    Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Endocr Relat Cancer; 2016 Jan; 23(1):27-34. PubMed ID: 26598713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.
    Kim SJ; Lee KE; Myong JP; Park JH; Jeon YK; Min HS; Park SY; Jung KC; Koo do H; Youn YK
    World J Surg; 2012 Feb; 36(2):310-7. PubMed ID: 22190222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF V600E mutation in papillary thyroid cancer is correlated with adverse clinicopathological features but not with iodine exposure.
    Özçelik S; Bircan R; Sarıkaya Ş; Gül AE; Aydın B; Özçelik M; Çelik M; Dayan A; Tütüncü Y; Cengiz H; Karadayı N; Gözü HI
    Endokrynol Pol; 2019; 70(5):401-408. PubMed ID: 31135058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Association between BRAF V600E mutation and central lymph node metastasis in patients with papillary thyroid carcinoma].
    Shi C; Qin H; Ding C; Sun Y; Lyu Y; Shi T
    Zhonghua Zhong Liu Za Zhi; 2015 Feb; 37(2):123-7. PubMed ID: 25975689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas.
    Sancisi V; Nicoli D; Ragazzi M; Piana S; Ciarrocchi A
    J Clin Endocrinol Metab; 2012 Sep; 97(9):E1745-9. PubMed ID: 22740704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
    Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
    Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRAF mutation positive papillary thyroid carcinoma is less advanced when Hashimoto's thyroiditis lymphocytic infiltration is present.
    Marotta V; Guerra A; Zatelli MC; Uberti ED; Di Stasi V; Faggiano A; Colao A; Vitale M
    Clin Endocrinol (Oxf); 2013 Nov; 79(5):733-8. PubMed ID: 23469895
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concomitant high expression of BRAFV600E, P-cadherin and cadherin 6 is associated with High TNM stage and lymph node metastasis in conventional papillary thyroid carcinoma.
    Zhao L; Jiang R; Xu M; Zhu P; Mo XM; Wang N; Chen GG; Liu ZM
    Clin Endocrinol (Oxf); 2016 May; 84(5):748-55. PubMed ID: 26285159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
    Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
    Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience.
    Pelizzo MR; Boschin IM; Barollo S; Pennelli G; Toniato A; Zambonin L; Vianello F; Piotto A; Ide EC; Pagetta C; Sorgato N; Torresan F; Girelli ME; Nacamulli D; Mantero F; Mian C
    Clin Chem Lab Med; 2011 Feb; 49(2):325-9. PubMed ID: 21175381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between lymphovascular invasion and clinicopathological features of papillary thyroid carcinoma.
    Sezer A; Celik M; Yilmaz Bulbul B; Can N; Tastekin E; Ayturk S; Ustun F; Guldiken S; Sut N
    Bosn J Basic Med Sci; 2017 May; 17(2):144-151. PubMed ID: 28284178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
    Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
    Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
    Kim TY; Kim WB; Rhee YS; Song JY; Kim JM; Gong G; Lee S; Kim SY; Kim SC; Hong SJ; Shong YK
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):364-8. PubMed ID: 16918957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clinical significance of BRAFV600E mutations in pediatric papillary thyroid carcinomas.
    Li Y; Wang Y; Li L; Qiu X
    Sci Rep; 2022 Jul; 12(1):12674. PubMed ID: 35879379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
    Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
    Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.